bullish
Pharmaron (康龙化成) A+H: Allocation and Thoughts on Trading
443 Views27 Nov 2019 17:08
Pharmaron, the second-largest contract research organization (CRO), raised USD 560 m at HKD 39.50/share. In this insight, we will cover the...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Pharmaron Buy Support21 Sep 2020
- Long Pharmaron/Short Wuxi: Take Profit Now, A-Share Pullback the Key Risk23 Jan 2020
- Pharmaron (康龙化成) Post-IPO: A/H Convergence Post Connect Inclusion Supports A Trade02 Jan 2020
- Pharmaron (康龙化成) A+H: Decent H/A Discount and Cornerstone Line-Up12 Nov 2019
- Pharmaron (康龙化成) A+H Listing: 3Q2019 Numbers and Thoughts on Valuation06 Nov 2019
x